|
|
|
| home > white papers > Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring - Dycem |
|
|
 WHITE PAPERS |
|
Dycem
|
|
Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring
|
|
A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
A Steriline Robotic Pilot Line as Core Asset for Shilpa Medicare Expansion in the Field of Oncology Drugs
Como, 01/07/2021 – Steriline and Shilpa Medicare Limited, one of
the largest specialty generic pharmaceutical companies in the world,
based in India, recently developed a cutting-edge filling, stoppering
and capping solution for injectable oncology products. The two companies
have been working together for more than 10 years, signing their first
collaboration when they were both emerging realities with expansion
strategies, and they have been growing together since then.
More info >> |
|
 |
White Papers |
 |
|
pAVEway™ expression system for the efficient expression of therapeutic proteins
Fujifilm Diosynth Biotechnologies
One of the major bottlenecks in the production of biopharmaceuticals is
the efficient expression of therapeutic proteins in microbial or
mammalian cells. The Escherichia coli pAVEway™ expression system
described here has been developed to ensure high product titres and
efficient scale up to GMP manufacture, whilst minimising many common
issues seen in other expression systems, such as ‘leaky’ expression
(expression of recombinant protein in the absence of inducer).
More info >> |
|
 |
Industry Events |
 |
Pharma Integrates 2021
16 November 2021, VIRTUAL CONFERENCE
Now in its tenth year, Pharma Integrates is a unique event bringing
together pharma and healthcare leaders across the Pharmaceutical
pipeline to address their needs, to share insights and create debate on
crucial topics that influence the future of patient outcomes.
More info >> |
|
|
|
